Community Research and Development Information Service - CORDIS

RNA-based anticancer therapies

Development of innovative therapeutic products relies strongly on the improved understanding of molecular and pathological mechanisms.
RNA-based anticancer therapies
The role of nucleolar RNA is still not fully elucidated but it is understood that this type of ribonucleic acid is involved in the regulation of normal growth. Israeli researchers have managed to develop a new method through which they can "silence" small nucleolar RNA in microbial species.

The species that were used were trypanosome species and the developed methodology relies on the RNA interference (RNAi) approach. This is a groundbreaking development given that the use of RNAi to silence small stable RNAs has not been documented.

The potential of this technology can be significant given that novel therapeutic modalities for the treatment of cancer and other pathologies can be developed based on this method. The research team is now seeking to outlicense rights to this technology. The ideal partner should possess expertise in the pharmaceutical development arena and be in a position to exploit the therapeutic and market potential of this technology.
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top